J Exp Clin Cancer Res 2008, 27:37.PubMedCrossRef 13. Caliaro MJ, Vitaux P, Lafon C, Lochon I, Néhmé A, Valette A, Canal P, Bugat R, Jozan S: Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer 1997, 75:333–340.PubMedCrossRef 14. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453–475.PubMedCrossRef 15. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell

D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H: The effects of adding zoledronic https://www.selleckchem.com/products/AZD8931.html acid to neoadjuvant chemotherapy SC79 mw on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010,102(7):1099–1105.PubMedCrossRef 16. Matsumotoa S, Kimura S, Segawab H, Kurodab J, Yuasab T, Satoa K, Nogawab M, Tanakaa F, Maekawab T, Wadaa H: Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.

Lung Cancer 2005, 47:31–39.CrossRef 17. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G: Quisinostat in vivo Repeated intermittent low-dose therapy with zoledronic acid induces an early, and sustained, isothipendyl and long lasting decrease of vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482–4486.PubMedCrossRef 18. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour

cells in women with locally advanced breast cancer: an open label, randomized, phase 2 trial. Lancet Oncol 2010,11(5):421–428.PubMedCrossRef 19. Gnant M, Mlineritsch B, Luschin-Ebengreuth GL, Kainberger F, Kassmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840–849.PubMedCrossRef 20. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983, 43:5379–5388.PubMed 21.